These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7442606)

  • 1. [Antithrombin III determinations in internal medicine and surgery].
    Schmitz-Huebner U
    Med Lab (Stuttg); 1980 Sep; 33(9):232-5. PubMed ID: 7442606
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antithrombin III (clinical aspects and methodology)].
    Abildgaard U
    Ric Clin Lab; 1978; 8 Suppl 2():90-7. PubMed ID: 106453
    [No Abstract]   [Full Text] [Related]  

  • 3. [Importance of the determination of thrombin-antithrombin-III complexes in hypercoagulability states].
    García Avello A; García Frade A; Sureda JL; Torrado MC
    Sangre (Barc); 1991 Apr; 36(2):163. PubMed ID: 1866654
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-thrombin III levels in some Malaysian patients suspected of having acquired coagulation disorders.
    Tan SH; Doraisamy G; Noriah R; Lopez CG
    Singapore Med J; 1983 Feb; 24(1):33-6. PubMed ID: 6867763
    [No Abstract]   [Full Text] [Related]  

  • 5. [Antithrombin-III activity in clotting disorders in polytraumatized patients (author's transl)].
    Sefrin P; Brunswig D; Wenzel M
    Dtsch Med Wochenschr; 1982 Mar; 107(10):383-5. PubMed ID: 7060468
    [No Abstract]   [Full Text] [Related]  

  • 6. [Antithrombin III: critical review of the methods used for its monitoring in thrombophilic states].
    Modiano A; Belisario A
    G Clin Med; 1981 Sep; 62(9):597-608. PubMed ID: 7033027
    [No Abstract]   [Full Text] [Related]  

  • 7. [Round table on the use of chromogenic substrates in hemostasiologic diagnosis].
    Vogel G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):189-200. PubMed ID: 6177604
    [No Abstract]   [Full Text] [Related]  

  • 8. [Significance of the amidolytic method in the typing of congenital antithrombin III deficiency].
    Losonczy H; Nagy I
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):184-8. PubMed ID: 6177603
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comparative studies on the determination of abnormal antithrombin III activity].
    Nagy I; Losonczy H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):180-3. PubMed ID: 6177602
    [No Abstract]   [Full Text] [Related]  

  • 10. [From clinical tests to etiology: analysis of clinical features. Coagulation disorders].
    Sakuragawa N
    Rinsho Byori; 1987 Dec; Spec No 75():135-44. PubMed ID: 3448279
    [No Abstract]   [Full Text] [Related]  

  • 11. Antithrombin III in Echis carinatus envenomation in northern Nigeria.
    Mba EC; Onyemelukwe GC
    Acta Haematol; 1989; 81(2):98-100. PubMed ID: 2496558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin and antithrombin 3.
    Stein ZL
    Arch Surg; 1979 Aug; 114(8):980. PubMed ID: 464818
    [No Abstract]   [Full Text] [Related]  

  • 13. Clotting times and antithrombin III activity in cats with naturally developing diseases: 85 cases (1984-1994).
    Thomas JS; Green RA
    J Am Vet Med Assoc; 1998 Nov; 213(9):1290-5. PubMed ID: 9810385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.
    Demers C; Henderson P; Blajchman MA; Wells MJ; Mitchell L; Johnston M; Ofosu FA; Fernandez-Rachubinski F; Andrew M; Hirsh J
    Thromb Haemost; 1993 Mar; 69(3):231-5. PubMed ID: 8470046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Blood clotting diagnosis with chromogenic substrates].
    Róka L; Rasche H
    Internist (Berl); 1980 Apr; 21(4):189-94. PubMed ID: 6998907
    [No Abstract]   [Full Text] [Related]  

  • 16. [Abnormal antithrombin III].
    Sakuragawa N
    Rinsho Byori; 1987 Apr; Spec No 70():187-201. PubMed ID: 3302389
    [No Abstract]   [Full Text] [Related]  

  • 17. [Antithrombin III in clinical practice].
    Monreal M; Rodríguez R; Monasterio I
    Med Clin (Barc); 1982 Jun 16-30; 79(2):91-3. PubMed ID: 7121115
    [No Abstract]   [Full Text] [Related]  

  • 18. Antithrombin III and plasminogen: a comparison of two synthetic substrate-based methods.
    Ito RK; Statland BE
    Am J Clin Pathol; 1983 Oct; 80(4):465-73. PubMed ID: 6624709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of hypercoagulable screens.
    Kovacs MJ
    Arch Intern Med; 2002 Mar; 162(5):613-4. PubMed ID: 11871942
    [No Abstract]   [Full Text] [Related]  

  • 20. [Hemostasis in untreated acute leukemia. II. Natural inhibitors: biological and immunological activity. Immunologic variation of antithrombin III].
    Kordich L; Sassetti B; Lago O
    Sangre (Barc); 1984; 29(2):133-40. PubMed ID: 6206579
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.